Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 17/20 | 0.79 |
| ▸ | CHUK | O15111 | 13/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518489 | 0.87 | IKBKB (0.62) | IKBKBCHUKJAK2 | |
| SCHEMBL27634134 | 0.85 | IKBKB (0.67) | IKBKBCHUKJAK2CCNE1CDK2 | |
| SCHEMBL6273867 | 0.85 | IKBKB (0.66) | IKBKBCHUKJAK2CCNE1CDK2 | |
| SCHEMBL4064476 | 0.84 | IKBKB (0.66) | IKBKBCHUKJAK2CCNE1CDK2 | |
| SCHEMBL4383162 | 0.83 | IKBKB (0.79) | IKBKBCHUKJAK2CCNE1CDK2 | |
| SCHEMBL3516525 | 0.83 | EPHX2 (0.61) | IKBKBCHUKJAK2CDK2EPHX2 | |
| SCHEMBL3518974 | 0.81 | IKBKB (0.56) | IKBKBCHUKJAK2CDK2EPHX2 | |
| SCHEMBL3521180 | 0.81 | IKBKB (0.67) | IKBKBCHUKJAK2CDK2MAPK8 | |
| SCHEMBL3599373 | 0.81 | IKBKB (0.67) | IKBKBCHUK | |
| SCHEMBL3518043 | 0.80 | IKBKB (0.74) | IKBKBCHUKJAK2CDK2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2004638-A1 | ANILINO-PYRIMIDINE PHENYL AND BENZOTHIOPHENE ANALOGS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120593-A1 | ANILINO-PYRIMIDINE PHENYL AND BENZOTHIOPHENE ANALOGS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | IKBKB 3482/4885CHUK 1792/4885JAK2 140/4885 |
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CHUK 2096/4885JAK2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.